Last reviewed · How we verify

Tislelizumab + SOX Chemotherapy

The First Affiliated Hospital with Nanjing Medical University · Phase 3 active Small molecule

Tislelizumab + SOX Chemotherapy is a PD-1 inhibitor + Chemotherapy Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently in Phase 3 development for Non-small cell lung cancer, PD-L1 positive, Small cell lung cancer, PD-L1 positive.

Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, thereby enhancing the body's immune response against cancer cells. SOX chemotherapy is a combination of platinum-based and anthracycline-based chemotherapeutic agents that work by inducing DNA damage and apoptosis in rapidly dividing cancer cells.

Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, thereby enhancing the body's immune response against cancer cells. SOX chemotherapy is a combination of platinum-based and anthracycline-based chemotherapeutic agents that work by inducing DNA damage and apoptosis in rapidly dividing cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Small cell lung cancer, PD-L1 positive.

At a glance

Generic nameTislelizumab + SOX Chemotherapy
SponsorThe First Affiliated Hospital with Nanjing Medical University
Drug classPD-1 inhibitor + Chemotherapy
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

The combination of Tislelizumab and SOX chemotherapy is thought to work synergistically to enhance the body's immune response against cancer cells while also inducing DNA damage and apoptosis in rapidly dividing cancer cells. This dual mechanism of action may lead to improved efficacy in treating certain types of cancer.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tislelizumab + SOX Chemotherapy

What is Tislelizumab + SOX Chemotherapy?

Tislelizumab + SOX Chemotherapy is a PD-1 inhibitor + Chemotherapy drug developed by The First Affiliated Hospital with Nanjing Medical University, indicated for Non-small cell lung cancer, PD-L1 positive, Small cell lung cancer, PD-L1 positive.

How does Tislelizumab + SOX Chemotherapy work?

Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, thereby enhancing the body's immune response against cancer cells. SOX chemotherapy is a combination of platinum-based and anthracycline-based chemotherapeutic agents that work by inducing DNA damage and apoptosis in rapidly dividing cancer cells.

What is Tislelizumab + SOX Chemotherapy used for?

Tislelizumab + SOX Chemotherapy is indicated for Non-small cell lung cancer, PD-L1 positive, Small cell lung cancer, PD-L1 positive.

Who makes Tislelizumab + SOX Chemotherapy?

Tislelizumab + SOX Chemotherapy is developed by The First Affiliated Hospital with Nanjing Medical University (see full The First Affiliated Hospital with Nanjing Medical University pipeline at /company/the-first-affiliated-hospital-with-nanjing-medical-university).

What drug class is Tislelizumab + SOX Chemotherapy in?

Tislelizumab + SOX Chemotherapy belongs to the PD-1 inhibitor + Chemotherapy class. See all PD-1 inhibitor + Chemotherapy drugs at /class/pd-1-inhibitor-chemotherapy.

What development phase is Tislelizumab + SOX Chemotherapy in?

Tislelizumab + SOX Chemotherapy is in Phase 3.

What are the side effects of Tislelizumab + SOX Chemotherapy?

Common side effects of Tislelizumab + SOX Chemotherapy include Fatigue, Nausea, Diarrhea, Vomiting, Anemia, Thrombocytopenia.

What does Tislelizumab + SOX Chemotherapy target?

Tislelizumab + SOX Chemotherapy targets PD-1 and is a PD-1 inhibitor + Chemotherapy.

Related